George Golumbeski, Director at Sage Therapeutics, Inc. (SAGE), bought 8,000 shares at $31.45 ($252K) on 2022-05-05, disclosed to the SEC on 2022-05-09.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| ENTA | SELL | 2019-03-06 | $962K | — | Filing → |
| ENTA | SELL | 2019-02-13 | $2.4M | — | Filing → |